Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
17 Mar. 2026
Strong Growth Outlook Drives 150% Oversubscription of Adimmune’s Syndicated Loan
Adimmune Corporation (TWSE: 4142) today signed a NT$4.5 billion syndicated loan agreement with a consortium of ten banks led by Land Bank of Taiwan. Reflecting strong confidence in Adimmune’s growth prospects and recognition of vaccines as a strategically critical industry, the facility was oversubscribed by 150%, demonstrating robust support from the financial sector.
11 Mar. 2026
Strengthening Taiwan–Japan Friendship: Adimmune Hosts Delegation from Chung Shan Medical University and Chiba Institute of Science
Adimmune Corporation (TWSE: 4142) recently welcomed a delegation of faculty members and students from Chung Shan Medical University in Taiwan and the health sciences program at Chiba Institute of Science in Japan for a facility visit.
06 Feb. 2026
Did you know the 1,000 Japanese yen banknote hides a story about the Tetanus Vaccine?
When traveling in Japan, everyone is surely familiar with the 1,000 yen banknote.
The dignified gentleman featured on it is Shibasaburō Kitasato, widely regarded as the “Father of Modern Japanese Medicine”—and a pioneer in therapeutic medicine who helped change the course of human history.
1889: Became the world’s first scientist to successfully culture Clostridium tetani, the bacterium that causes tetanus.
